Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership
BOZEN,
that on the heels of its recent partnership announcement with McKesson, it
has received categorical support from virtually all of its 13 North American
customers in just a few days since the partnership was publicly announced.
While several customers’ hospital policies prevent them from publicly
commenting on industry events, a few reactions to the McKesson-Health
Robotics partnership [CytoCare Robot only] were cleared for publication.
“We have seen McKesson’s announcement that it has become the exclusive
North American strategic partner for Health Robotics’ CytoCare, an Oncology
I.V. Admixtures Robot implemented at our hospital in early 2008. We went
“live” about a year ago and have since utilized CytoCare to prepare patient
doses from as many as 60 different drug vials of antibiotic, chemotherapy,
and/or monoclonal antibody therapies for Ampicillin, Busulfan, Carboplatin,
Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine,
Daunorubicin, Doxurubicin, Epirubicin, Etoposide, Fluororacil, Ganziclovir,
Gemzar, Idarubicin, Ifosfamide, Irinotecan, Melphalan, Mesna, Methotrexate,
Mitoxantrone, Oxaliplatin, Paclitaxel, Rituximab, Vinblastin, Vincristine,
and Vinorelbine. CytoCare has filled patient doses with three different
brands of 50ml to 1L i.v. Bags (Baxter Viaflex, B|Braun PAB, B|Braun Excel)
and Becton Dickinson PlastiPak syringes in 3, 10, and 60cc sizes. The
University of Colorado Hospital is a long-standing customer of McKesson
Corporation, and looks forward to extending our relationship ever farther,”
stated
“We have been following the recent developments in I.V. robotics by
multiple start-up companies and have evaluated alternative technologies at
both
We noticed that all of these start-up companies have ideas with merit, but
thought their service infrastructure in
developed. We will be taking delivery of i.v.STATION in two to three months
and will be conducting a validation trial of the technology. We plan to
utilize i.v.STATION for batch compounding of parenteral doses including
serial dilutions, and we will utilize the robot for patient-specific doses
after the interface to our McKesson Clinical System is complete. Given the
fact that Health Robotics’ HL7 interface technology is identical for both
CytoCare and i.v.STATION, we are very pleased to see the announcement of the
McKesson-Health Robotics strategic partnership and are confident that it will
only make our i.v.STATION HL7 interface efforts smoother. In addition, it is
very reassuring to see such a mature and omnipresent service organization
like McKesson Corporation endorse Health Robotics’ technology. We look
forward to expand our relationship with McKesson Corporation,” stated
Bush
“At Allegiance Health we have been following robotics applications for
hospital pharmacy for over a decade. In the last two years we have focused on
I.V. robotics, especially the worldwide progress of Health Robotics. During
the last twelve months we have worked closely with Health Robotics and are
taking delivery of i.v.STATION in October. We have also completed capital
budget approval for the purchase of CytoCare. While we have always been
impressed with Health Robotics’ products and the commitment of their
executive leadership such as Gaspar DeViedma, we have had some concerns with
the ability of Health Robotics as a non-
that could provide responsive, experienced, customer-focused service, and
support required for this sophisticated technology in
McKesson-Health Robotics strategic partnership announcement is a great
match-up, and definitely puts to bed any support or service concerns we had
in the past,” stated
“We are very excited to see American customers’ overwhelming support for
the McKesson partnership, and to compare and contrast such positive feedback
with prior comments about much needed local improvements in skill,
experience, competence, and commitment to service standards. We look forward
to McKesson taking over Help Desk, Tier 1 and Tier 2 support, Implementation
Activities, Spare Parts Inventory, Professional Training, FDA Regulatory
assistance, HL7 Interface Engineering, and all other service activities that
needed local improvement according to our American customers, and leave only
Tier 3 support, manufacturing, and R&D activities to Health Robotics, as was
originally planned and regulated in prior distribution contracts. While there
is expected to be much “noise” and “spin” about our partnership decisions, we
wish to let our customers set the record straight about CytoCare [which has
never been in doubt as far as the product's capabilities], and from October
onwards, to also start to vouch for McKesson’s service. CytoCare is a complex
and revolutionary technology that requires highly-skilled engineers and a
sizeable service commitment, which is why we are very pleased to have
partnered with a world-class service and engineering organization such as
McKesson Automation,” stated
About Health Robotics:
Health Robotics is the global leading supplier of life-critical
intra-venous medication preparation, compounding, and dispensing Robots,
providing healthcare facilities in four continents with robotics technology
and software automation solutions. The world-leading solutions CytoCare
[hazardous IVs], i.v.STATION [non-hazardous IVs], i.v.SOFT [workflow engine]
and the future development of TPNstation, have and will greatly contribute to
ease global hospitals’ growing pressures to improve patient safety through
the effective and efficient production of sterile, accurate, and
ready-to-administer IVs, to eliminate life-threatening drug-exchange errors,
to decrease other medication errors and sterility risks, and to work more
efficiently, increase throughput, reduce waste, and contain costs. For more
information, please visit http://www.health-robotics.com
For additional information, please contact:
Health Robotics
Gaspar G. DeViedma
Europe: +39(346)963-4934
USA: +1(609)-980-7976
gaspar.deviedma@health-robotics.com
SOURCE Health Robotics